BioTelemetry, Inc. Reports Third Quarter 2013 Financial Results Signs Exclusive

Agreement to Service Kaiser Permanente

BioTelemetry, Inc. (BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the third quarter ended September 30, 2013.

Operational Highlights:

• 18% revenue growth as compared to the third quarter of 2012
• Achieved profitability on an adjusted basis for the second consecutive quarter
• Generated positive adjusted EBITDA of $3.6 million, the highest quarterly EBITDA in four years
• Reduced consolidated DSO to 51 days, a 10 day improvement compared to year end 2012

  Published: 06 November 2013

  Written by Editor

  Nasdaq   Healthcare   Financial Results   Up on News   Interesting News  

  Read more: BioTelemetry Inc ( BEAT )

ZELTIQ Announces Third Quarter 2013 Financial Results

 Raises 2013 Financial Guidance

    Total revenue of $29.5 million, up 64% year-over year and 12% sequentially
    System revenue of $15.9 million, up 87% year-over-year and 22% sequentially
    Consumable revenue of $13.6 million, up 44% year-over-year and 2% sequentially
    181 systems shipped, bringing total system installed base to 1,912

ZELTIQ^(R) (ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced financial results for the third quarter 2013.

NuVasive Announces Third Quarter 2013 Financial Results

NuVasive, Inc. (NASDAQ: NUVA)

• Third quarter 2013 revenue of $169.2 million; up 14.0% from third quarter 2012
  
• Non-GAAP operating margin of 15.4%
  
• GAAP net income of $7.5 million, or $0.16 per share
  
• Non-GAAP net income of $18.3 million, or $0.39 per share
  
• Increases 2013 guidance for revenue, non-GAAP operating margin, and non-GAAP earnings per share
  

NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today financial results for the quarter ended September 30, 2013.

BSD Reports Increasing European Market Penetration by Terumo for MicroThermX® Microwave Ablation System

BSD Medical Corporation (BSDM) (“Company” or “BSD”) today reported that Terumo Europe NV (Terumo), a wholly owned subsidiary of Terumo Corporation, has already introduced the MicroThermX^® Microwave Ablation System (MicroThermX) into the major markets in Europe, including Germany, France and Spain.

Terumo has performed numerous clinical procedures throughout Europe, which has led to enhanced clinical acceptance and greater market penetration. The market potential in the 100 countries included in the Terumo contract is in excess of $1 billion in annual sales. As a result of the increased clinical acceptance, Terumo continues to increase their purchases of MicroThermX generators and antennas.